Red-shifted opsin molecules and uses thereof
The invention, in some aspects, relates to compositions and methods for altering cell activity and function. The invention also relates, in part, to the use of light-activated ion pumps (LAIPs) such as a light-activated ion pump polypeptide that when expressed in an excitable cell and contacted with a red light silences the excitable cell, wherein the polypeptide sequence of the light-activated ion pump comprises a wild-type or modified halomicrobium or haloarcula halorhodopsin polypeptide sequence.
1. An isolated light-activated ion pump polypeptide that when expressed in a mammalian excitable cell and contacted with a red light silences the excitable cell, wherein the polypeptide sequence of the light-activated ion pump comprises an amino acid sequence set forth herein as SEQ ID NO:2 having a K→R substitution at the amino acid residue corresponding to amino acid 200 or an amino acid sequence set forth herein as SEQ ID NO:2 having a K→R and a W→F substitution at the amino acid residues corresponding to amino acids 200 and 214 respectively.
2. An isolated light-activated ion pump polypeptide that when expressed in a mammalian excitable cell and contacted with a red light silences the excitable cell,
wherein the polypeptide sequence of the light-activated ion pump comprises an amino acid sequence set forth herein as SEQ ID NO:2, with one, two, or more amino acid sequence modifications, and wherein the polypeptide has at least 70% amino acid identity to the sequence set forth as SEQ ID NO:2,
wherein the polypeptide sequence comprises a K→R modification and a W→F modification at the amino acid residues corresponding to amino acid 200 and 214, respectively, of the amino acid sequence of Halo57 (SEQ ID NO:2).
3. The isolated light-activated ion pump polypeptide of claim 2 , wherein the polypeptide sequence is the sequence set forth as SEQ ID NO:26.
4. A vertebrate cell comprising a light-activated ion pump polypeptide that when expressed in a mammalian excitable cell and contacted with a red light silences the excitable cell, wherein the polypeptide sequence of the light-activated ion pump comprises an amino acid sequence set forth herein as SEQ ID NO:2, with one, two, or more amino acid sequence modifications, and wherein the polypeptide has at least 70% amino acid identity to the sequence set forth as SEQ ID NO:2, and wherein the polypeptide sequence comprises one or more of:
a) a K→R, K→H, or K→Q substitution at an amino acid residue corresponding to amino acid 200 of the amino acid sequence of Halo57 (SEQ ID NO:2);
b) a T→S substitution at an amino acid residue corresponding to amino acid 111 of the amino acid sequence of Halo57 (SEQ ID NO:2);
c) a T→S substitution at an amino acid residue corresponding to amino acid 203 of the amino acid sequence of Halo57 (SEQ ID NO:2); or
d) a K→Q+W→F double substitution at the amino acid residues corresponding to amino acid 200 and 214, respectively, of the amino acid sequence of Halo57 (SEQ ID NO:2).
5. The vertebrate cell of claim 4 , wherein the polypeptide has the amino acid sequence of Gene4 (SEQ ID NO:4); Gene58 (SEQ ID NO:6); Gene56 (SEQ ID NO:8); or Gene55 (SEQ ID NO:10); and wherein the amino acid sequence comprises one or more of
a) a K→R, K→H, or K→Q substitution at an amino acid residue corresponding to amino acid 200 of the amino acid sequence of Halo57 (SEQ ID NO:2);
b) a T→S substitution at an amino acid residue corresponding to amino acid 111 of the amino acid sequence of Halo57 (SEQ ID NO:2);
c) a T→S substitution at an amino acid residue corresponding to amino acid 203 of the amino acid sequence of Halo57 (SEQ ID NO:2); or
d) a K→Q+W→F double substitution at the amino acid residues corresponding to amino acid 200 and 214, respectively, of the amino acid sequence of Halo57 (SEQ ID NO:2).
6. A method of hyperpolarizing a cell, the method comprising,
a) expressing in a mammalian cell an isolated light-activated ion pump polypeptide that when expressed in an excitable cell and contacted with a red light silences the excitable cell, wherein the polypeptide sequence of the light-activated ion pump comprises an amino acid sequence set forth herein as SEQ ID NO:2, with one, two, or more amino acid sequence modifications, and wherein the polypeptide has at least 70% amino acid identity to the sequence set forth as SEQ ID NO:2; and
b) contacting the isolated light-activated ion pump with a light that activates the isolated light-activated ion pump and hyperpolarizes the cell.
7. The method of claim 6 , wherein the polypeptide sequence comprises one or more of:
a) a K→R, K→H, or K→Q substitution at an amino acid residue corresponding to amino acid 200 of the amino acid sequence of Halo57 (SEQ ID NO:2);
b) a T→S substitution at an amino acid residue corresponding to amino acid 111 of the amino acid sequence of Halo57 (SEQ ID NO:2);
c) a T→S substitution at an amino acid residue corresponding to amino acid 203 of the amino acid sequence of Halo57 (SEQ ID NO:2); or
d) a K→Q+W→F double substitution at the amino acid residues corresponding to amino acid 200 and 214, respectively, of the amino acid sequence of Halo57 (SEQ ID NO:2).
8. The method of claim 6 , wherein the polypeptide sequence comprises a K→R modification and a W→F modification at amino acid residues corresponding to amino acids 200 and 214, respectively, of the amino acid sequence of Halo57 (SEQ ID NO:2).
9. The method of claim 8 , wherein the polypeptide sequence is the sequence set forth as SEQ ID NO:26.
10. A method of treating a disorder in a vertebrate subject, the method comprising:
a) administering to a vertebrate subject in need of such treatment, a therapeutically effective amount of a light-activated ion pump polypeptide that when expressed in an excitable cell and contacted with a red light silences the excitable cell, wherein the polypeptide sequence of the light-activated ion pump comprises a polypeptide sequence comprising an amino acid sequence set forth herein as SEQ ID NO:2, with one, two, or more amino acid sequence modifications, and wherein the polypeptide has at least 70% amino acid identity to the sequence set forth as SEQ ID NO:2;
b) expressing the light-activated ion pump polypeptide in an excitable cell in the subject; and
c) contacting the light-activated ion pump polypeptide with a light that activates the light-activated ion pump polypeptide and hyperpolarizes the cell, to treat the disorder.
11. The method of claim 10 , wherein the light-activated ion pump is administered in the form of a cell, wherein the cell expresses the light-activated ion pump; or in the form of a vector, wherein the vector comprises a nucleic acid sequence encoding the light-activated ion pump and the administration of the vector results in expression of the light-activated ion pump in a cell in the subject.
12. The method of claim 10 , wherein the polypeptide sequence comprises one or more of:
a) a K→R, K→H, or K→Q substitution at an amino acid residue corresponding to amino acid 200 of the amino acid sequence of Halo57 (SEQ ID NO:2);
b) a T→S substitution at an amino acid residue corresponding to amino acid 111 of the amino acid sequence of Halo57 (SEQ ID NO:2);
c) a T→S substitution at an amino acid residue corresponding to amino acid 203 of the amino acid sequence of Halo57 (SEQ ID NO:2); or
d) a K→Q+W→F double substitution at the amino acid residues corresponding to amino acid 200 and 214, respectively, of the amino acid sequence of Halo57 (SEQ ID NO:2).
13. The method of claim 10 , wherein the polypeptide sequence comprises a K→R modification and a W→F modification at the amino acid residues corresponding to amino acid 200 and 214, respectively, of the amino acid sequence of Halo57 (SEQ ID NO:2).
14. The method of claim 10 , the polypeptide sequence is the sequence set forth as SEQ ID NO:26.
15. The cell of claim 4 , wherein the cell is an excitable cell.
16. The cell of claim 4 , wherein the cell is a mammalian cell.
17. The cell of claim 4 , further comprising one, two, three, four, or more additional light-activated ion pumps, wherein one, two, three, four, or more of the additional light-activated ion pumps is activated by contact with light having a non-red light wavelength.
18. The method of claim 6 , wherein the cell is in vivo, ex vivo, or in vitro.
19. The method of claim 6 , wherein the cell further comprises one, two, three, or more additional light-activated ion pumps, wherein one, two, three, four, or more of the additional light-activated ion pumps is activated by contact with light having a non-red light wavelength.